Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study)

被引：0
|
作者：
Segal, N. H. [1 ]
Reidy-Lagunes, D. [1 ]
Capanu, M. [1 ]
Kemeny, N. [1 ]
Chung, K. [1 ]
Kelsen, D. [1 ]
Hollywood, E. [1 ]
Goodman-Davis, N. [1 ]
Saltz, L. B. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4087
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Bevacizumab plus infusional 5-fluorouracil,leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy:A pilot study
    Hyuk-Chan Kwon
    Sung Yong Oh
    Suee Lee
    Sung-Hyun Kim
    Hyo-Jin Kim
    World Journal of Gastroenterology, 2007, (46) : 6231 - 6235
  • [22] Phase I study of gefitinib in combination with irinotecan in patients with fluoropyrimidine refractory advanced colorectal cancer (CRC).
    Chau, I
    Massey, A
    Higgins, L
    Botwood, N
    Cunningham, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 263S - 263S
  • [23] Phase II Study of S-1 and Irinotecan Plus Bevacizumab as Second-line Treatment for Patients With Metastatic Colorectal Cancer Resistant to the Fluoropyrimidine-oxaliplatin-cetuximab Regimen
    Tanioka, Hiroaki
    Shimada, Ken
    Tsuji, Akihito
    Kochi, Mitsugu
    Kim, Ho Min
    Takahashi, Takao
    Denda, Tadamichi
    Takagane, Akinori
    Watanabe, Takanori
    Kotaka, Masahito
    Nakamura, Masato
    Sunakawa, Y. U.
    Takeuchi, Masahiro
    Ichikawa, Wataru
    Fujii, Masashi
    ANTICANCER RESEARCH, 2022, 42 (05) : 2675 - 2681
  • [24] Cetuximab plus bevacizumab in patients (pts) with metastatic colorectal cancer (mCRC) who have failed on irinotecan, oxaliplatin and fluoropyrimidines-based chemotherapy
    Souglakos, J.
    Kalbakis, K.
    Vamvakas, N.
    Kalykaki, A.
    Kotsakis, A.
    Agelaki, S.
    Karampeazis, A.
    Gioulbasanis, J.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Phase I Study of Bevacizumab Plus Irinotecan in Pediatric Patients with Recurrent/Refractory Solid Tumors
    Okada, Keiko
    Yamasaki, Kai
    Tanaka, Chika
    Fujisaki, Hiroyuki
    Osugi, Yuko
    Hara, Junichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (11) : 1073 - 1079
  • [26] A phase II study of cetuximab (Erbitux®) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer
    Koo, Dong Hoe
    Lee, Jae-Lyun
    Kim, Tae Won
    Chang, Heung Moon
    Ryu, Min-Hoe
    Lee, Sung Sook
    Kim, Min Kyoung
    Sym, Sun Jin
    Lee, Jung Shin
    Kang, Yoon-Koo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2007, 22 : S98 - S103
  • [27] A phase I/II study of arfolitixorin and 5-fluorouracil in combination with oxaliplatin (plus or minus bevacizumab) or irinotecan in metastatic colorectal cancer
    Carlsson, G.
    Koumarianou, A.
    Guren, T. K.
    Haux, J.
    Katsaounis, P.
    Kentepozidis, N.
    Pfeiffer, P.
    Braendengen, M.
    Mavroudis, D.
    Taffin, H.
    Skintemo, L.
    Tell, R.
    Papadimitriou, C.
    ESMO OPEN, 2022, 7 (05)
  • [28] Phase II study of S-1 in combination with irinotecan in patients with advanced colorectal cancer (CRC)
    Komatsu, Y
    Yuuki, S
    Amano, T
    Machida, N
    Ozasa, M
    Kato, T
    Furukawa, S
    Akita, H
    Asaka, M
    Sakata, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 297S - 297S
  • [29] A phase II study of trifluridine/tipiracil, irinotecan, and bevacizumab in pretreated metastatic colorectal cancer (TABAsCO)
    Gupta, Medhavi
    Fountzilas, Christos
    Vijayvergia, Namrata
    Attwood, Kristopher
    Hochster, Howard S.
    Mukherjee, Sarbajit
    Iyer, Renuka V.
    Boland, Patrick Mckay
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [30] Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial
    Yoshihiko Nakamoto
    Masafumi Noda
    Ryuichi Mikami
    Yukihiko Tokunaga
    Tatsuo Okumoto
    Takashi Kawamura
    Hidetoshi Fujiwara
    Sadayuki Doi
    Naohiro Tomita
    International Journal of Clinical Oncology, 2020, 25 : 1285 - 1290
12345